Indrayani Biotech Ltd (INDRANIB) — shareholding pattern, promoter holding, financials and share price
About Indrayani Biotech Ltd (INDRANIB)
Indrayani Biotech Ltd operates in the Other Agricultural Products industry, within the Fast Moving Consumer Goods sector. It trades on the NSE as INDRANIB and on the BSE under scrip code 526445. Its ISIN is INE007C01021.
Incorporated in 1992, Indrayani Biotech Ltd is in the business of Foods & Hospitality, Engineering and Healthcare [1]
Indrayani Biotech Limited, incorporated in 1992, initially focused on horticulture products like cut flowers and hybrid seeds. Its current core business is the manufacture of electric motors and distribution of electrical apparatus.
The company has undergone several strategic shifts and restructurings, including significant equity reduction and mergers, transforming from agriculture to industrial manufacturing.
Listed peers in Other Agricultural Products: Universal Starch Chem Allied Ltd, Agri-Tech (India) Ltd, Unisem Agritech Ltd, Flex Foods Ltd, IB Infotech Enterprises Ltd, Unique Organics Ltd.
Valuation & Returns
10 Jul 2026At ₹7.95 a share on 10 Jul 2026, Indrayani Biotech Ltd (INDRANIB) was valued at a price-to-earnings ratio of 67.9x against an industry P/E of 33.81x and a price-to-book of 0.5x on a book value of ₹15.92 per share as of Mar 2025. Solomo computes return on equity of -10.12% and return on capital employed of 2.57% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2025 to Dec 2025.
- P/E
- 67.9x
- Industry P/E
- 33.81x
- P/B
- 0.5x
- EPS (TTM)
- ₹-1.61
- Book value / share
- ₹15.92
- ROE
- -10.12%
- ROCE
- 2.57%
- ROA
- -2.74%
- Debt / equity
- 1.89x
- Dividend yield
- 0%
- EBITDA margin
- 7.31%
- 52-week range
- ₹6.69 – ₹18.08
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Indrayani Biotech Ltd (INDRANIB) reported revenue of ₹130 crore, net profit of ₹-6 crore and earnings per share of ₹-0.78. That compares with revenue of ₹165 crore and net profit of ₹10 crore in Mar 2024. Figures are consolidated, as filed with the exchanges.
In the quarter ended Dec 2025, revenue was ₹35.01 crore and net profit ₹0.11 crore (consolidated).
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 21 | 61 | 163 | 165 | 130 |
| Net profit (₹ cr) | -11 | 4 | 12 | 10 | -6 |
| EPS (₹) | -1.91 | 0.76 | 1.49 | 0.81 | -0.78 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | - | -5.42% | -13.32% | -21.66% |
| Profit growth | - | 12.37% | -30.05% | -158.64% |
| Stock price CAGR | 0% | -5% | -53% | -50% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 33.26% of Indrayani Biotech Ltd (INDRANIB) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 3.13%. Promoters have pledged 24.6% of their holding. Market capitalisation was ₹36 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Mar 2026: Jayaseelan Singaravelu 8.8%, Sonal Lohia 3.92%, Ajitkumar C Patel 2.85%, Lrsd Securities Pvt Ltd 2.03%, HUF 1.69%, S Prakash 1.66%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 33.26% | 24.6% | - | 3.13% | 66.74% |
| Dec 2025 | 33.26% | 24.6% | - | 3.13% | 66.74% |
| Sep 2025 | 33.26% | 2.5% | - | 3.13% | 66.74% |
| Jun 2025 | 33.28% | 24.6% | - | 3.11% | 66.72% |
| Mar 2025 | 33.28% | 24.6% | - | 3.66% | 66.72% |
| Dec 2024 | 33.28% | 18.1% | - | 5.25% | 66.72% |
| Sep 2024 | 33.4% | 15.1% | - | 5.59% | 66.6% |
| Jun 2024 | 33.48% | 15% | - | 6.79% | 66.52% |